{"schema_version":"secwatch.filing_event.v1","accession":"0000010795-24-000015","form_type":"8-K","ticker":"BDX","cik":"0000010795","company_name":"BECTON DICKINSON & CO","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.307648+00:00","generated_at":"2026-06-06T10:34:58.346693+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BD Q1 revenue $4.7B (+2.6% YoY), GAAP EPS $0.96, adj. EPS $2.68; raises FY2024 guide","bullets":["Q1 revenue $4,706M, up 2.6% as reported, 2.4% organic; currency-neutral growth 1.6%.","GAAP diluted EPS $0.96 vs. $1.70 prior year; adjusted diluted EPS $2.68 vs. $2.98.","Company raises full-year adjusted EPS guidance and midpoint of organic revenue growth guidance.","BD Medical launched SiteRite 9 Ultrasound System; BD Life Sciences received FDA clearance for MiniDraw Capillary Blood Collection System.","BD signed World Economic Forum's Zero Health Gaps Pledge, reinforcing health equity commitment."],"urls":{"canonical":"https://secwatch.observer/filing/0000010795-24-000015","json":"https://secwatch.observer/filing/0000010795-24-000015.json","markdown":"https://secwatch.observer/filing/0000010795-24-000015.md","text":"https://secwatch.observer/filing/0000010795-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000001079524000015/0000010795-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000001079524000015/bdx-20240201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:34:58.346693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}